Where does RK Pharma Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), RK Pharma Inc. ranks #33,091 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does RK Pharma Inc. hold?

RK Pharma Inc. holds 8 US utility patents granted between 2022 and 2025, spanning 4 technology areas.

What is RK Pharma Inc.'s Innovation Score?

RK Pharma Inc. has an Innovation Score of 37.8 out of 100 (top 43% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does RK Pharma Inc. focus on?

RK Pharma Inc.'s top technology area is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes) with 6 patents. Grants appear in 4 CPC subclasses total.

Is RK Pharma Inc.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for RK Pharma Inc..

What does claim depth mean for RK Pharma Inc.'s patents?

RK Pharma Inc.'s patents average 5.3 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the RK Pharma Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

RK Pharma Inc.

USPTO PatentsView assignee record - 8 granted patents across 4 technology areas, recorded in grant years 2022–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61K (Preparations FOR Medical, Dental OR Toiletry Purposes).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, RK ranks #33,091 of 49,997 tracked US assignees by granted-patent volume, with 8 patents across 4 technology areas.

#33,091
of 49,997 US assignees by volume: Top 43%
by Innovation Score (37.8/100): 5.3
avg claims per patent

USPTO PatentsView assignee plate

Corpus R33091 · US Corporation #33,091 · 8 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-SPARSE · TYPE-USCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 8 grants
MID-PACK #33,091/49,997
PHOTO-FINISH Rich Media Ventures
CPC-NARROW A61K · 4 areas
INNOV-THIN 37.8/100
CLAIMS-SPARSE 5.3 claims/avg
TYPE-USCORP US Corporation
SPAN-YRS 2022–2025 · 4y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Rich Media Ventures, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
RK Pharma · this assignee

38
3D Lighting… · lowest

7

What this shows RK's Innovation Score is 37.8/100 (top 43% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where RK's grants concentrate

RK Pharma Inc. is a focused PatentsView assignee: 4 CPC subclasses with 75% of grants classified under A61K (Preparations FOR Medical, Dental OR Toiletry Purposes). Peak complete grant year is 2023 (3 grants) versus a trough of 1 in 2024. By volume, RK sits between Rich Media Ventures, LLC and Robit OYJ.

RK's three-year grant acceleration

RK Pharma Inc. shows 6 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Rich Media Ventur…

8
Rios Intelligent…

8
Riri

8
River2sea

8
RL RND and IP Hol…

8
Rlmb Group

8
RMB Importing

8
Robit OYJ

8
RK Pharma ◀

8

What this shows RK holds 8 patents at rank #33,021, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near RK

By rank, the assignees closest to #33,021 in granted patent volume.

Leaders in A61K (Preparations FOR Medical)

Other assignees with the most granted patents in RK's primary technology class.

RK's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

38 Top 43% higher than 57% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2022–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2022–2019 baseline. Full figures in the table below.

View data table

RK Pharma Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2022	2	25.0%
2023	3	37.5%
2024	1	12.5%
2025partial year	2	25.0%

Which technologies does RK Pharma Inc. patent most?

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 6

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 2

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 1

C07D - Heterocyclic Compounds 1

Top 4 of 4 technology areas

Where it ranks

Overall rank by patents

#33,091

of 49,997 tracked assignees

Innovation Score

37.8 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

RK Pharma Inc.'s patent record in context - here's where to go next.

RK Pharma Inc.'s lead technology class is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes), 75% of its portfolio - see every assignee active in that class. Explore A61K
Ranked #33,091 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare RK Pharma Inc. against Rich Media Ventures, LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 37.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.